Android app Apple app link

DexCom (DXCM) Slid on Poor Execution and GLP-1 Drug Disruption Concerns

By Yahoo! Finance   |   3 weeks ago
DexCom (DXCM) Slid on Poor Execution and GLP-1 Drug Disruption Concerns

Sands Capital's Q4 2024 investor letter highlighted their Select Growth Fund's performance, focusing on companies leading in economic transformation. The fund outperformed the Russell 1000 Growth Index but noted DexCom, Inc.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

To become a member, please download and purchase membership through our app.